In a move designed to expand access to the oral COVID-19 antiviral treatment, the US Food and Drug Administration has authorized pharmacists to prescribe Pfizer Inc.'s Paxlovid (nirmatrelvir/ritonavir) under certain conditions. Paxlovid has emerged as the leading treatment to prevent COVID-19 from worsening in patients at high risk of severe outcomes, but prescribing restrictions and the logistics of getting the treatment to patients within five days after symptoms begin have limited use of the treatment.
The FDA's Center for Drug Evaluation and Research (CDER) announced the revision to the emergency use authorization (EUA) for Paxlovid...
